Phase II trial for uveitis - MM-093

Issues concerning developments in care of Ocular Inflammatory Disease and other noteworthy Items are contained in this forum.

Moderators:Mike Bartolatz, kwork

Post Reply
Mike Bartolatz
Joined:Fri Feb 06, 2004 9:58 pm
Phase II trial for uveitis - MM-093

Post by Mike Bartolatz » Wed May 16, 2007 10:46 pm

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Pilot Study of
MM-093 in Patients with Autoimmune Uveitis
CAMBRIDGE, Mass., April 4, 2007 – Merrimack Pharmaceuticals, Inc. today announced the
initiation of a Phase 2 pilot study to determine the safety and efficacy of its immunomodulator
MM-093 in patients suffering from autoimmune uveitis. MM-093, Merrimack's lead product, is a
recombinant version of human alpha-fetoprotein (AFP).
Uveitis is an autoimmune inflammatory disease that produces eye pain, light sensitivity, and
diminished vision, including blindness. Sarcoid and birdshot are rare uveitis subtypes, which
could be classified as Orphan indications due to their small patient size.
The randomized, double-blind, placebo-controlled, Phase 2 study is being conducted at the
Massachusetts Eye Research and Surgery Institute in Cambridge, Massachusetts under the
direction of C. Stephen Foster, MD, a world-renowned expert in uveitis and Clinical Professor of
Ophthalmology at Harvard Medical School. The objective of this study is to examine the safety
and efficacy of MM-093 in approximately 20 patients with either sarcoid or birdshot uveitis.
Patients will discontinue their current therapy for uveitis and be treated with MM-093 or placebo
for up to 36 weeks. This study is a flare design where the number of patients whose uveitis
relapses after discontinuing the use of their background therapy will be assessed at the end of
the study. Patients who experience a flare of uveitis during the study will be retreated with their
original therapy.
“Uveitis remains a significant cause of blindness in developed countries, and immunosuppressive
chemotherapy and systemic corticosteroid therapy continue to form the backbone for ocular
immunologists trying to preserve the vision of patients who are going blind from uveitis. However,
such therapies can cause significant, potentially serious side effects,” said Dr. Foster, principal
investigator for the study. “MM-093 is a particularly promising immunomodulatory molecule from
a risk/benefit standpoint, with very little likelihood of exposing patients to the side effects of
corticosteroid or of immunosuppressive therapy.”
Merrimack controls a strong intellectual property estate around MM-093 including fourteen issued
patents and a number of pending applications, both in the U.S. and internationally, which cover
composition of matter, production methods and therapeutic uses of the drug.
Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and
development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its
lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid
arthritis, psoriasis or with autoimmune uveitis. MM-093 is an investigational drug and has not
been approved by the U.S. Food and Drug Administration or any international regulatory agency.
The company's proprietary Network Biology discovery platform, developed with the help of
leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks
as a basis for improved validation, lead identification and speed in the development of innovative,
effective and safe therapeutics. Merrimack is a privately held company based in Cambridge,
Massachusetts. For additional information, please visit
Contact: Kathleen Petrozzelli, Manager, Corporate Communications, 617-441-1043
Mike Bartolatz

Mike Bartolatz
Joined:Fri Feb 06, 2004 9:58 pm

update on MM-093

Post by Mike Bartolatz » Mon Mar 17, 2008 3:39 pm

Mike Bartolatz

Mike Bartolatz
Joined:Fri Feb 06, 2004 9:58 pm

Re: Phase II trial for uveitis - MM-093

Post by Mike Bartolatz » Sun Feb 08, 2009 11:15 am

Mike Bartolatz

Post Reply